Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro

Journal of Neuro-Oncology

Volumn 43, Issue 2, 1999, Pages 109-114

  Moreira, André Luís ^a,b   Friedlander, David Raul ^a   Shif, Bronya ^a   Kaplan, Gilla ^b   Zagzag, David ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Endothelial cell; SP1; Thalidomide; Thalidomide analogue

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CC 1069; CELL EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CELL CULTURE; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORNEA; ENDOTHELIUM CELL; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INFLAMMATION; RABBIT;

ANIMALS; CELL DIVISION; CORNEA; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; RABBITS; SP1 TRANSCRIPTION FACTOR; THALIDOMIDE; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 0032865755     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006202700039     Document Type: Article

References (28)

1. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC: Histopathology, classification, and grading of gliomas. Glia 15: 211-221, 1995
2. Libermann TA, Friesel R, Jaye M, Lyall RM, Westermark B, Drohan W, Schmidt A, Maciag T, Schlessinger J: An angiogenic growth factor is expressed in human glioma cells. EMBO J 6: 1627-1632, 1987
3. Zagzag, D: Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol 146: 293-309, 1995
4. Zagzag D, Miller DC, Sato Y, Rifkin DB, Burstein DE: Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 50: 7393-7398, 1990
5. Folkman J: Anti-angiogenesis: new concepts for therapy of solid tumors. Ann Surg 175: 409-416, 1972
6. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 175: 699-703, 1991
7. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibition action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 177: 1675-1680, 1993
8. Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner JD, Rom W, Kaplan G: Thalidomide treatment reduces tumor necrosis factor α production and enhances weight gain in patients with pulmonary tuberculosis Mol Med 1: 384-397, 1995
9. Moreira AL, Tsenova-Berkova L, Wang J, Laochumroonvorapong P, Freeman S, Freedman VH, Kaplan G: Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuberc Lung Dis 78: 47-55, 1997
10. Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Therap 6: 303-306, 1965
11. Gardner-Medwin JMM, Smith NJ, Powell RJ: Clinical experience with thalidomide in the management of severe oral and genital ulcerations in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53: 828-832, 1994
12. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ: Thalidomide as treatment of refractory aphtous ulceration related to human immunodeficiency virus infection. Clin Inf Dis 20: 250-254, 1995
13. Vogelsang GB, Taylor S, Gordon G, Hess AD: Thalidomide, a potent agent for the treatment of graft-versus-host disease. Transplant Proc 4: 904-906, 1986
14. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994
15. Fine HA: Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Neur Clin 13: 827-846, 1995
16. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, Kaplan G: Selection of novel analogues of thalidomide with enhanced tumor necrosis factor α inhibitory activity. Mol Med 2: 506-515, 1996
17. Leibovich SP, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N: Macrophage-induced angiogenesis is mediated by tumor necrosis factor α. Nature 329: 630-632, 1987
18. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC: Dual role of tumor necrosis factor α in angiogenesis. Am J Pathol 40: 539-544, 1992
19. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis alpha-dependent angiogenesis. Mol Cell Biol 17: 4015-4023, 1997
20. Shono T, Ono M, Izumi H, Jimi S, Matsushima K, Okamoto T, Kohno K, Kuwano M: Involvement of transcription factor NF-κB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 16:4231-4239, 1996
21. Neish AS, Khachigian LM, Park A, Baichwal VR, Collins T: SP1 is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. J Biol Chem 270: 28903-28909, 1995
22. 1 integrins. Cancer Res 56: 1939-1947, 1996
23. Kondo S, Asano M, Suzuki H: Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 194: 1234-1241, 1993
24. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846, 1993
25. Tischer B, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. J Biol Chem 266: 11947-11954, 1991
26. Patterson C, Perella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber B: Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem 270: 23111-23118, 1995
27. Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW, Freedman VH, Kaplan G: Thalidomide and thalidomide analogues reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Human Retrov 13: 857-863, 1997
28. Patterson C, Wu Y, Lee ME, DeVault JD, Runge MS, Haber E: Nuclear protein interactions with the human KDR/flk-1 promoter in vivo. Regulation of SP1 binding is associated with cell type-specific expression. J Biol Chem 272: 8410-8416, 1997